UFP TECHS INC. DL-,01

UFP Technologies positions itself as a CDMO for medical technology and targets combined annual growth of 12–18% through organic growth and targeted acquisitions. Management aims for a mid‑term gross margin of 28–31% and an adjusted operating margin of 17–20%; annual revenue is around USD 600 million and market capitalization about USD 2.5 billion. UFP reports it has under 1% share of the roughly USD 100 billion outsourcing market but sees long‑term potential and an acquisition pipeline of 5–10 opportunities. Higher inventories and receivables are weighing on short‑term cash flow but, according to management, stem from customer‑bound finished goods and reflect demand. » More on de.investing.com

UFP Technologies reported adjusted EPS of $2.92 and revenue of $173.96 million for Q2 2026, comfortably topping consensus estimates. Revenue rose 15.1% year-over-year, organic growth was 12.4%, and gross margin improved to 29.3%. The MedTech business showed broad strength across multiple product lines and customers, and management says operational issues at AJR have been resolved. Management expects organic growth for 2026 within the long-term target range of 6–9%; the stock rose about 11% in premarket trading and surpassed its 52-week high. » More on de.investing.com

UFP Technologies’ stock rose to a new 52-week high of $275.20 as it approaches a market capitalization of $2.12 billion. The share gained 9.13% last week; year-to-date the increase is 19.41% (one‑year return 5.06%). InvestingPro rates the stock as overvalued relative to its fair value and signals an overbought RSI. UFP reported strong Q1 results with EPS of $2.48 versus $2.14 expected, but narrowly missed revenue expectations ($154.2 million vs. $154.6 million); the stock dipped slightly in after-hours trading. » More on de.investing.com